NADAC acquisition cost data for BUTRANS 7.5 MCG/HR PATCH. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
| 59011075704 | $113.66 | 2022-01-01 | Rx |
Generic: Buprenorphine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $43.8M | 77,211 | 17,100 | $141.03 |
| 2020 | $36.9M | 59,807 | 11,590 | $152.58 |
| 2021 | $28.0M | 41,931 | 8,090 | $164.53 |
| 2022 | $24.8M | 34,410 | 6,703 | $176.66 |
| 2023 | $23.2M | 30,688 | 6,514 | $185.67 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $3.8M | 4,910 | 1,085 |
| North Carolina | $1.3M | 1,743 | 408 |
| Texas | $1.2M | 1,612 | 338 |
| Georgia | $1.2M | 1,548 | 342 |
| Florida | $1.1M | 1,387 | 265 |
| Pennsylvania | $1.1M | 1,512 | 342 |
| Oklahoma | $1.0M | 1,289 | 281 |
| Colorado | $678.9K | 926 | 284 |
| New York | $670.8K | 897 | 179 |
| Ohio | $626.4K | 891 | 198 |
| Massachusetts | $600.5K | 827 | 173 |
| Tennessee | $547.1K | 678 | 146 |
| Missouri | $539.0K | 713 | 154 |
| Indiana | $538.2K | 656 | 146 |
| Wisconsin | $525.2K | 711 | 162 |
| Michigan | $500.5K | 680 | 154 |
| Virginia | $495.2K | 653 | 145 |
| Alabama | $490.0K | 643 | 120 |
| Washington | $485.5K | 647 | 145 |
| Arkansas | $468.4K | 609 | 119 |
| South Carolina | $400.8K | 528 | 89 |
| Arizona | $382.6K | 497 | 138 |
| Illinois | $375.8K | 476 | 100 |
| Connecticut | $338.9K | 431 | 78 |
| New Jersey | $337.0K | 467 | 97 |
| Minnesota | $316.7K | 498 | 135 |
| Idaho | $239.3K | 330 | 62 |
| Oregon | $228.0K | 281 | 53 |
| Kentucky | $219.9K | 307 | 72 |
| Nebraska | $215.8K | 331 | 95 |
| Maryland | $204.1K | 270 | 72 |
| Mississippi | $191.0K | 264 | 57 |
| Louisiana | $177.1K | 244 | 58 |
| Maine | $166.6K | 223 | 57 |
| South Dakota | $155.3K | 220 | 34 |
| Iowa | $154.7K | 245 | 39 |
| West Virginia | $147.7K | 214 | 44 |
| New Hampshire | $134.7K | 154 | 35 |
| Utah | $131.7K | 155 | 45 |
| Kansas | $123.3K | 176 | 36 |
| Montana | $111.2K | 167 | 40 |
| Nevada | $88.1K | 129 | 31 |
| Wyoming | $81.0K | 95 | 14 |
| Vermont | $64.4K | 97 | 20 |
| Delaware | $61.7K | 72 | 23 |
| Rhode Island | $60.3K | 74 | 15 |
| New Mexico | $48.7K | 64 | 13 |
| Puerto Rico | $34.1K | 68 | N/A |
| Alaska | $28.9K | 34 | N/A |
| District of Columbia | $14.6K | 18 | N/A |
| North Dakota | $13.3K | 18 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.